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Many regions of the Epstein–Barr virus (EBV) genome, repeated and unique
sequences, contribute to the geographical variation observed between
strains. Here we use a large alignment of curated EBV genome sequences
to identify major sites of variation in the genome of type 1 EBV strains;
the CAO deletion in latent membrane protein 1 (LMP1) is the most frequent
major indel present in the unique regions of EBV strains from various parts
of the world. Principal component analysis was used to identify patterns of
sequence variation and nucleotide positions in the sequences that can dis-
tinguish EBV from some different geographical regions. Viral genome
sequence variation also affects interpretation of genetic content; known
genes, origins of replication and gene expression control regions explain
most of the viral genome but there are still a few sections of unknown func-
tion. One of these EBV genome regions contains a large inverted repeat
sequence (invR) within the IR-1 major internal repeat array. We deleted
this invR sequence and showed that this abolished the ability of the virus
to transform human B cells into lymphoblastoid cell lines.
This article is part of the theme issue ‘Silent cancer agents: multi-disciplinary
modelling of human DNA oncoviruses’.1. Introduction
Most of the genetic map of Epstein–Barr virus (EBV) is occupied by known
genes or other genetic elements, whose functions have been demonstrated
experimentally (annotated in the reference EBV genome sequence NC007605).
The approximately 172 kb genome of EBV includes many different tandem
repeated sequences. Some of these are within the open reading frames and
are expressed as sections of repetitive protein structure within certain EBV pro-
teins. Some other repeat regions are not in open reading frames but have
specific functions [1]. The largest repeat (IR-1 or major internal repeat) com-
prises about 6.6 copies of a 3072 nt sequence; it includes the Wp promoter
and some exons of the Epstein-Barr nuclear antigen (EBNA) mRNAs. These,
however, only account for about half the IR-1 repeat sequence and IR-1 also
contains a large open reading frame (BWRF1). No mRNA has yet been found
for BWRF1 [2]. The BWRF1 open reading frame and an inverted repeat
sequence (invR) within it are both conserved in EBV strains [3].
Our recent studies have provided Epstein–Barr virus (EBV) genome
sequences from a wide range of worldwide geographical locations, both from
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2diseases associated with EBV and from healthy infected
people [4–6]. There are large variations in the incidence of
some EBV-associated diseases in different parts of the
world. The incidence of EBV-associated nasopharyngeal car-
cinoma (NPC) is about 50-fold higher in Cantonese parts of
Southern China than in western countries; EBV-associated
Burkitt’s lymphoma (BL) is frequent in sub-Saharan Africa
and natural killer/T cell lymphomas containing EBV are rela-
tively frequent in some Asian countries. In contrast,
infectious mononucleosis (owing to delayed primary infec-
tion by EBV) is common in Western countries [1]. Host
genetic risk, behavioural/lifestyle factors, co-infections and
environmental carcinogens account for some of the difference
in incidence but differences in EBV strains endemic in differ-
ent parts of the world may also contribute to disease
incidence [1]. Natural variation of the gp350 and gp42 EBV
glycoproteins [6], which are the antigens being used in cur-
rent efforts to make an EBV vaccine, may also be relevant
to the universal application of the vaccine.
Although a phylogenetic tree is an effective way of analys-
ing viral genome sequence relationships (for example fig. S1 of
[6]), there are theoretical difficulties in using that method with
long sequences that diversify through inter-strain recombina-
tion [7] and there is also no direct way to deduce which
nucleotide positions determine the different branches of the
phylogeny. We have previously reported the extensive histori-
cal recombination apparent in EBV strain sequences [4]. We
used principal component analysis (PCA) to identify regions
of the genome that correspond to major components of vari-
ation [4,6]. The type 1/type 2 difference is the major form of
variation and the sequences within the EBV genome that
determine the differences between type 1 and type 2 EBV
have been described previously using this dataset [6].
In this paper we analyse the geographical variation
between EBV strains, using PCA to identify individual nucleo-
tides in the viral genome that are sufficient to distinguish some
of the main patterns of geographical variation of viral strains.
The large repeat arrays in the EBV genome remain a challenge
for sequence analysis because the standard Illumina sequence
reads are not long enough to span the repeat units. Alternative
methods that give longer sequence reads (PacBio, Oxford
Nanopore) can be used on cloned viral DNA but are not
suitable for the very low fraction of viral DNA in clinical
samples or EBV infected cell lines. The hybrid enrichment
protocols that have been used to increase sequencing efficiency
[4,6] involve fragmenting the DNA, again limiting the length
of sequence reads. However, progress has been made in
de-convoluting the IR-1 repeat region [3] and here we use
our recently improved genetic method for modifying EBV
repeats [8] to show the essential requirement for a large
inverted repeat sequence (invR) present in each copy of IR-1
for transformation of human B cells by EBV.
2. Methods
The 241 EBV genome sequences [6] studied here (listed in elec-
tronic supplementary material, table S1) were aligned using
MAFFT [9], inserting gaps (shown as – in the sequences) to
achieve the multiple sequence alignment (MSA). Some manual
editing was used to reduce gapping in repeat sequence align-
ments. The prototypic reference EBV sequence is Accession
Number NC007605, which is a chimaera of B95-8 and Raji
EBV. The gapping in the MSA means that the MSA has a
length of 178 176 nt compared to the 171 823 nt of NC007605.Only the 217 type 1 EBV genomes from the MSA were used
in the analysis of geographical variation shown in this paper. Of
the 178 176 nucleotide locations in the MSA, 7708 were found to
have a single nucleotide polymorphism (compared to the con-
sensus) in five or more genomes. This provided a 7708  217
matrix of SNP locations as the basis for our search for those
nucleotides that could be associated with the geographical vari-
ation observed. The PCA technique adopted was performed
using a singular value decomposition procedure from the
Delphi/Pascal-based SDL Component Suite (http://www.loh-
ninger.com). An initial transformation of the matrix enabled
the 7708 eigenvector coefficients to be derived in less than a
minute on a desktop computer. As before [6], the PCA in this
paper counts gaps in the MSA in addition to the usual single
nucleotide polymorphisms (SNPs).
Construction of the invR deletion mutant of the B95-8 EBV
bacterial artificial chromosome (BAC) used a procedure analo-
gous to our recent study of EBNA-LP [8] to introduce the
deletion into all copies of IR-1. Briefly, the invR nucleotides
15 407–15 917 (EBV NC007605 numbering) were replaced by a
15 bp linker containing restriction sites in a single BamHI frag-
ment of IR-1 (and in the first partial IR-1 repeat upstream of
the first BamHI site) by PCR. Gibson assembly was used to con-
struct a repeat array of 6.6 tandem copies of this mutated IR-1
repeat that was recombined into the W4 EBV BAC lacking IR-1
as described previously [8], generating invR-deleted EBV. To
construct a revertant, the invR-deleted EBV IR-1 region was
deleted by recombineering and replaced with a wild-type
repeat array. Full details of the sequences used, procedures and
verification of the recombined viruses are available online [10].
The B cell transformation assay using indicated green Raji units
(GRU) of virus [11] with 106 B cells per ml and western blot
for EBNA-LP using antibody JF186 [12] were as described [8,10].
3. Results
(a) Multiple sequence alignment file
We recently reported [6] some preliminary analysis of a mul-
tiple sequence alignment (MSA) of a total of 241 EBV
genomes. This 43 Mb MSA file is now provided as electronic
supplementary material, figure S1 in fasta format; it forms the
basis of the EBV sequence analysis described in this paper
and in [6]. The details of all the strains in the MSA including
GenBank accession numbers have been described previously
[6]; electronic supplementary material, table S1 lists the stan-
dard strain names [6] together with the decorated names of
EBV strains used in electronic supplementary material,
figure S1 that allow representation of the geographical
origin and other features in the PCA. The first three com-
ponents of variation in the 241 sequences in the MSA
account for 45% of the variation and readily separated the
type 1 from the type 2 sequences [6]. PC1 was 26.9%, PC2
was 12.1% and PC3 was 6.1% of the variation. Geographical
separation of strains is also apparent in these PCA results ([6]
and figure 1a,b). In this conventional presentation of the PCA
(figure 1a,b), each point in the figure corresponds to one EBV
genome sequence. The position of the point corresponds to
the sum of the eigenvector coefficients for those positions in
the sequence that have a SNP relative to the consensus
sequence.
(b) Major indels in the BART miRNA and LMP1 regions
In an initial approach to find genome sequences that might
determine geographical clustering, we had identified some
geographical groups of type 1 strains which clustered closely
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Figure 1. Principal component analysis of type 1 EBV sequence diversity coloured by geographical origin (colours as shown in part a) using 217 type 1 EBV strains (a) PC-1
versus PC-3, (b) PC-2 versus PC-3. PC-1 versus PC-2 with the same dataset is shown in fig. 1B of [6]. (c) Eigenvector coefficients plotted with a smoothing window of 20 nt
along the MSA genome (plotted as sum of coefficients on the ordinate axis). Labelled peaks are listed in electronic supplementary material, figure S2. PNG, Papua New Guinea.
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3in a phylogenetic tree [6] and PCA (figure 1a,b), which were
considered characteristic of a geographical region. These
groups of isolates from Indonesia, Papua New Guinea,
Africa (Kenya) and China were relatively homogeneous and
comparison of SNPs between their consensus sequences
and a consensus of all 217 type 1 sequences provides one
approach to identifying the variation (electronic supplemen-
tary material, figure S2). To focus on the main points of
variation, nucleotide locations were only included in these
analyses when the number of occurrences of SNPs at the
location in question was greater than 5. The number of
SNPs at each of these greater than 5 locations was plotted
for each group separately as cumulative SNPs in a 100 nt
window and this identified regions and peaks of difference
(electronic supplementary material, figure S2). Many of
these peaks were at similar genome locations in several of
the geographical groups and were in repeat arrays but there
were some differences. The gene regions corresponding to
the electronic supplementary material, figure S2 peaks arelisted in electronic supplementary material, table S2. We pre-
viously reported [6] the insertion in the BART region of the
genome (electronic supplementary material, table S2),
between miR BART8 and miR BART21, in 21 of the 241
strains analysed.
In fact, the most frequent major indel detected by this
type of analysis (peak 167798 in electronic supplementary
material, figure S2) is a 30 nt region of the LMP1 gene and
is known as the CAO deletion. It was originally identified
in a Chinese nasopharyngeal carcinoma sample [13] and its
functional consequences for LMP1 have been studied exten-
sively, summarized in [14]. LMP1 with this deletion is more
effective at activating NF-kB [14] and is more tumorigenic
in rodent fibroblasts or epithelial cells implanted into nude
mice [15–17]. The 30 bp CAO deletion is very uniform in
those strains that have it (see nucleotide positions 173 802–
173 831 in electronic supplementary material, figure S1) and
we can now estimate its varying prevalence in different geo-
graphical regions (figure 2). Overall, it was present in 99 of
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Figure 2. CAO deletion incidence in EBV strains from different geographical
regions. The filled part of the boxes indicates the number of CAO strains within
the total, also expressed as a percentage for each strain. PNG, Papua New Guinea.
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Epstein–Barr virus genome
The presentation of results in electronic supplementary
material, figure S2, plotting number of SNPs in a sliding
window, tends to accentuate regions where many SNPs are
clustered together and thus mostly picked out repeat arrays
or larger indels (electronic supplementary material, table
S2). Plotting the coefficients for each of the first three eigen-
vectors (figure 1c) showed the broad regions of the EBV
genome that contribute to the distributions in the PCA and
the locations of those main peaks are also listed in electronic
supplementary material, table S2, with some details of their
corresponding EBV genome region.
To focus more specifically on some single SNPs that con-
tribute strongly to the geographical separation observed in
the PCA plots and phylogenetic tree (figure 1 and [6]), we
plotted the PC2 and PC3 coefficients of all the nucleotide pos-
itions that contribute to the PCA of geographical groups of
EBV strains. In this alternative presentation of the PCA, the
eigenvector coefficients for all sequences in the chosen
group are averaged at each of the 7708 positions in the EBV
genome that have a SNP and thus contribute to the PCA.
Each point in figure 3 thus corresponds to one nucleotide
location in the MSA. All 7708 positions are plotted
(figure 3), but most of the values are small and cluster
around zero. The larger coefficients (which contribute
strongly to the PCA) can be seen in figure 3 and there were
three clearly distinct patterns of nucleotide position contri-
butions (figure 3), which corresponded to three major
clades seen in the phylogenetic tree of type 1 EBV strains
[6]. Europe, Africa and USA strains were in the same major
clade of the phylogenetic tree [6] but then separated within
that clade. Indonesia and Papua New Guinea were in another
major clade of the phylogenetic tree and have similar patterns
in figure 3. Asian strains were in a separate clade and have a
unique pattern in figure 3. By choosing a unique region from
the larger coefficients of each pattern, we obtained lists of
MSA positions that distinguished these geographical regions
(electronic supplementary material, table S3). The full geo-
graphical separations in the PCA involve many small
contributions distributed all along the genome (figure 1c),but the selected positions were sufficient to characterize an
EBV genome into one of these groups. Studies on EBV trans-
mission will require SNPs that can distinguish EBV strains
and this type of analysis can identify such strain markers.
SNPs in LMP1 and EBNA3 genes were prominent in some
of these lists but not in others, and many other gene regions
were represented (electronic supplementary material, table
S3); these will facilitate future studies that require markers
of EBV strains.
In this analysis we have not distinguished between EBV
sequences from cancer cases and normal infections (details
listed in [6]) because it appears that the type 1/type 2 and
geographical differences are much larger. This is illustrated
in a PCA plot in which contributions are coloured red for
cancer or green for normal (electronic supplementary
material, figure S3). There is no systematic difference in the
patterns at this level of analysis, so interpreting the patterns
of variation we have observed in this paper in type 1 EBV
strains as geographical is not confounded by the mixture of
cancer and normal strains present in the dataset.
(d) Repeat arrays and use of viral genetics to determine
functional significance in the IR-1 repeat
Because the size of repeat units within several of the EBV
repeat arrays is greater than paired Illumina sequence read
lengths, it is difficult to assign individual reads to any indi-
vidual copy of the repeat. This limits the analysis of the
large repeat arrays in the EBV genome. Mutating all the
copies of a repeat array is also challenging with the conven-
tional BAC genetics that is used in herpesvirus research.
Small variations in the sequence of individual repeat copies
can allow deconvolution of the reads and construction of
parts of the repeat array. We did this successfully for the
IR-1 major internal repeat [3]. The IR-1 region (figure 4a) is
important because it encodes the Wp promoter for initial
expression of the EBNA mRNAs upon infection. In addition
to some of the exons for EBNA-LP, a long open reading frame
(BWRF1) is present in the IR-1 sequence (figure 4a); BWRF1
was found to be conserved (or to be even longer than in
the reference NC007605) in most EBV strains [3].
No protein product has yet been identified for BWRF1
and part of that region of the IR-1 nucleotide sequence
includes a large inverted repeat [18] known as the invR struc-
ture (figure 4a). As a first step to determining if these genetic
features play a functional role in EBV, we constructed a
mutated EBV strain in which all seven copies of the invR
sequence are deleted from the B95-8 IR-1 repeat array. The
invR deletion also removes the 50 end of BWRF1 (figure 4a).
The mutagenesis was done using a novel approach to BAC
genetic engineering we described recently [8] and a revertant
strain was also made. Infection of primary human B cells
with several clones of this invR-deleted virus was compared
with the prototype B95-8 BAC virus and revertant virus; out-
growth of EBV-transformed lymphoblastoid cells was
measured. The deletion completely blocked B cell transform-
ation (figure 4b) but the revertant virus was similar to the
prototype virus, indicating the phenotype was owing to the
deletion of the invR sequence. To test whether the deletion
simply inactivated gene expression from Wp, we also super-
infected Raji cells with the prototype or the invR deletion
virus. Expression of EBNA-LP from the infecting virus (its
EBNA-LP has a different size on the SDS gel from the
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Figure 3. PCA nucleotide contribution plots of geographical groups identify three major patterns consistent with three major clades in the phylogenetic tree of
type 1 sequences. Nucleotide positions from the marked areas, which were chosen to characterize differences between the geographical groups, are listed in
electronic supplementary material, table S3.
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5endogenous EBNA-LP in Raji cells) was similar with both
wild-type and invR deletion strains, indicating that Wp is
still functional and that the RNA splicing events required to
make EBNA-LP protein are not prevented by the invR
deletion.4. Discussion
Known viral genes, origins of replication and gene expression
control regions explain most of the EBV genome but there are
still a few sections of completely unknown function. One of
these regions is the inverted repeat sequence (invR) within
the IR-1 major internal repeat array. Deleting this invR
sequence abolished the ability of the virus to transform
human B cells into lymphoblastoid cell lines. The invR del-
etion did not affect the expression of EBNA-LP from the
incoming viral genome in superinfected Raji cells, so it
appears that Wp function and the splicing of EBNA-LP
RNAs are not compromised in those cells. The deletion
removes part of the BWRF1 open reading frame and theintron containing invR has also been reported to produce
a stable RNA (ebv-sisRNA-2) in the nucleus [19]. This
ebv-sisRNA-2 has recently been found to bind several cell
regulatory proteins [20], so it is possible that our invR
mutation affects cell transformation through that type
mechanism. Also, it is not currently known whether
BWRF1 is actually expressed as a protein in EBV-infected
cells; no antibody for the protein is available and a survey
of stable mRNAs from that region of the EBV genome did
not show abundant RNA in the BWRF1 region in LCLs [2].
The strong effect of the new mutation we have identified
here will, however, justify further investigation of BWRF1
expression and the role of the invR sequence. The time
course of expression of the EBNA RNAs during infection
approximately follows their distance from the Wp promoter,
so its proximity to Wp suggests that it may be important to
look very early after infection for BWRF1 expression.
Using a combination of PCA and SNP counting, we ident-
ified some regions of the genome that contribute to
geographical variation (figure 3, electronic supplementary
material, figure S2, tables S2 and S3 and ref. [6]). There are
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Figure 4. (a) Diagram of two IR-1 repeat units, numbered according to the NC007605 reference EBV sequence, showing the positions of the deletions of the
inverted repeat invR. The locations of the BWRF1 open reading frame and the known Wp promoter region are marked, together with the W0, W1 and W2
exons of RNA expressed from Wp. The relationship between IR-1 and the repeated BamHI W restriction fragment is also indicated. (b) Transformation assay
for human B lymphocytes using wild-type, revertant or invR deletion mutant virus strains. C33, W3-4, W1-11 and A29 are different producer lines for the
wild-type virus and D6-62, D2-7 and D2-16 are producer lines for the invR-deleted virus. 1-3 and 21-7 are revertant virus strains. Virus titre is the quantity
of virus (in green Raji units—GRU) added to 106 B cells and the outcome is scored as cell proliferation observed under the microscope 2 days after infection
or lymphoblastoid cell line (LCL) outgrowth two weeks after infection. (c) Upper panel: EBNA-LP western blot showing endogenous protein in Raji cells and
the extra EBNA-LP (arrowed) from superinfecting virus 2 days after infection with wild-type (WT) or invR (D2) virus. Uninfected Raji cells (U) do not have
that band. Positions of size markers 46 kD and 58 kD are indicated. Lower panel: Same as upper panel but assayed 2 h after addition of virus, showing that
the extra band is absent so was not owing to protein present in the virus preparation but a consequence of viral gene expression in the super-infected cells.
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6both distributed local sequence variations and localized
differences in repeat copy numbers or indels at several
locations. The SNP counting approach that we used identifies
all of these, but the visualization using the accumulated SNPs
in a sliding window tends to emphasize the indels, since
our approach characterizes each nucleotide gap as an inde-
pendent SNP. Choosing SNPs with high eigenvector
coefficients that clustered in the PCA plots (figure 3) allowed
identification of localized SNPs (electronic supplementary
material, table S3), which will be useful as strain markers in
future studies of EBV transmission. Combinations of the
indels that we focused on are sufficient to discriminatebetween the geographical regions, but the more distributed
local sequence variations also play an important role in
distinguishing the variants.
The incidence of EBV-associated diseases varies greatly in
different parts of the world [1]. The selective presence of the
viral genome in these diseases offers great opportunities for tar-
geted therapy and early detection of disease. Immunization
against EBV is likely to be able to prevent infectious mononu-
cleosis [21] and EBV-based immunotherapies are being
investigated for some typesof cancer.Understanding thenatural
variation in EBV genome sequences is important because this
provides a background upon which mutations or sequence
royalsocietypublishing.org/journal/rstb
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evant to the diseases, diagnostic techniques or potential
therapies. There is already some evidence for mutations in
EBV being linked to certain types of cancer. For example,
about 10% of African BL cases contain EBV with a deletion of
the EBNA2 locus, which has been proposed to result in a
higher expression of the EBV BHRF1 homologue of the anti-
apoptosis BCL2 protein [22]. Also, mutations in the EBNA3B
gene have been shown tomake EBVmore oncogenic, producing
disease similar to diffuse large B cell lymphoma (DLBCL) in a
mouse model system and EBNA3B mutations have been
found in human DLBCL, BL and Hodgkin’s lymphoma cases
[23]. The V3 variant of the EBV Zp promoter (which contains
an additional NFAT binding site) causes increased expression
of BZLF1 and the EBV lytic replication cycle [24]. The V3 Zp is
enriched in cases ofAfricanBL [24] andChinese and Indonesian
NPC[6], suggestinga role forenhancedviral replication indevel-
opment of those diseases. Because of the different geographical
incidences of EBV-associated diseases, it is important to under-
stand the geographical variation of EBV to provide a context
for additional identification of cancer risk alleles.Our collection of 241 EBV genome sequences (with 217
type 1 EBV sequences) includes samples from many diseases
and from healthy people from different parts of the world [6]
but their distribution is unbalanced, so it is limited in its ability
to correlate variation with disease. It is, however, very useful as
a first step in identifying the variation that exists and will pro-
vide the basis for more targeted studies focused on specific
diseases, and the functional diversity of viral proteins.
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